Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Reneo Pharmaceuticals (NASDAQ: RPHM) announced participation in five investor conferences throughout September 2021. The events include the Citi 16th Annual BioPharma Conference from September 8-10, H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, Baird’s 2021 Global Healthcare Conference on September 15, SVB Leerink CybeRx Series on September 22-23, and Cantor Fitzgerald’s Virtual Global Healthcare Conference on September 30. Reneo focuses on therapies for rare genetic mitochondrial diseases, currently developing REN001 for improved cellular energy production.

IRVINE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that management will be participating in five investor conferences during the month of September.

Details for the upcoming conferences are as follows:

Conference: Citi 16^th Annual BioPharma Conference
Date: September 8-10, 2021
Format: One-on-one investor meetings

Conference: H.C. Wainwright 23^rd Annual Global Investment Conference
Date: September 13-15, 2021
Format: Presentation available for on-demand viewing (beginning 7:00am ET, September 13); one-on-one investor meetings

Conference: Baird’s 2021 Global Healthcare Conference
Date: September 15, 2021
Time: 1:20-1:50 PM PT
Format: Presentation and one-on-one investor meetings

Conference: SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines
Date: September 22-23, 2021
Format: One-on-one investor meetings

Conference: Cantor Fitzgerald’s Virtual Global Healthcare Conference
Date: September 30, 2021
Time: 8:40-9:10 AM ET
Format: Presentation and one-on-one investor meetings

About Reneo Pharmaceuticals

Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

Contacts:

Joyce Allaire
Managing Director
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Vinny Jindal
Chief Financial Officer
Reneo Pharmaceuticals, Inc.
investors@reneopharma.com

FAQ

What conferences is Reneo Pharmaceuticals attending in September 2021?

Reneo Pharmaceuticals will attend five investor conferences, including the Citi 16th Annual BioPharma Conference, H.C. Wainwright 23rd Annual Global Investment Conference, Baird’s 2021 Global Healthcare Conference, SVB Leerink CybeRx Series, and Cantor Fitzgerald’s Virtual Global Healthcare Conference.

What is the focus of Reneo Pharmaceuticals?

Reneo Pharmaceuticals is focused on developing therapies for patients with rare genetic mitochondrial diseases.

What is REN001 and its purpose?

REN001 is being developed by Reneo Pharmaceuticals to enhance mitochondrial function and increase ATP production, which is vital for cellular energy.

When is the Baird’s 2021 Global Healthcare Conference?

The Baird’s 2021 Global Healthcare Conference will be held on September 15, 2021.

How can I watch Reneo Pharmaceuticals' presentations at the H.C. Wainwright Conference?

Reneo Pharmaceuticals will have a presentation available for on-demand viewing starting at 7:00am ET on September 13, 2021.